120 related articles for article (PubMed ID: 31439330)
1. Impact of Conversion From Cyclosporine to Tacrolimus on Glucose Metabolism and Cardiovascular Risk Profiles in Long-Term Stable Kidney Transplant Recipients.
Lim JH; Hwang I; Cho JH; Kwon E; Jung HY; Choi JY; Park SH; Kim YL; Kim HK; Huh S; Won DI; Kim CD
Transplant Proc; 2019 Oct; 51(8):2697-2703. PubMed ID: 31439330
[TBL] [Abstract][Full Text] [Related]
2. Improved cardiovascular risk profile and renal function in renal transplant patients after randomized conversion from cyclosporine to tacrolimus.
Artz MA; Boots JM; Ligtenberg G; Roodnat JI; Christiaans MH; Vos PF; Blom HJ; Sweep FC; Demacker PN; Hilbrands LB
J Am Soc Nephrol; 2003 Jul; 14(7):1880-8. PubMed ID: 12819249
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular risk profile after conversion from cyclosporine A to tacrolimus in stable renal transplant recipients.
Baid-Agrawal S; Delmonico FL; Tolkoff-Rubin NE; Farrell M; Williams WW; Shih V; Auchincloss H; Cosimi AB; Pascual M
Transplantation; 2004 Apr; 77(8):1199-202. PubMed ID: 15114085
[TBL] [Abstract][Full Text] [Related]
4. Conversion from cyclosporine microemulsion to tacrolimus in stable kidney transplant patients with hypercholesterolemia is related to an improvement in cardiovascular risk profile: a prospective study.
Marcén R; Chahin J; Alarcón A; Bravo J
Transplant Proc; 2006 Oct; 38(8):2427-30. PubMed ID: 17097957
[TBL] [Abstract][Full Text] [Related]
5. Conversion from Tacrolimus to Cyclosporine A Improves Glucose Tolerance in HCV-Positive Renal Transplant Recipients.
Handisurya A; Kerscher C; Tura A; Herkner H; Payer BA; Mandorfer M; Werzowa J; Winnicki W; Reiberger T; Kautzky-Willer A; Pacini G; Säemann M; Schmidt A
PLoS One; 2016; 11(1):e0145319. PubMed ID: 26735686
[TBL] [Abstract][Full Text] [Related]
6. Effects of calcineurin inhibitors on paraoxonase and arylesterase activity after a kidney transplant.
Kahvecioglu S; Ersoy A; Gullulu M; Dirican M
Exp Clin Transplant; 2014 Aug; 12(4):334-42. PubMed ID: 24447269
[TBL] [Abstract][Full Text] [Related]
7. Conversion from cyclosporine microemulsion to tacrolimus-based immunoprophylaxis improves cholesterol profile in heart transplant recipients with treated but persistent dyslipidemia: the Canadian multicentre randomized trial of tacrolimus vs cyclosporine microemulsion.
White M; Haddad H; Leblanc MH; Giannetti N; Pflugfelder P; Davies R; Isaac D; Burton J; Chan M; Azevedo E; Howlett J; Ignaszewski A; Busque S; Cantarovich M; Ferguson R; Genest J; Ross H
J Heart Lung Transplant; 2005 Jul; 24(7):798-809. PubMed ID: 15982605
[TBL] [Abstract][Full Text] [Related]
8. Long-term follow-up after conversion from tacrolimus to cyclosporin in renal transplant patients with new-onset diabetes mellitus after transplantation.
Batista F; Auyanet I; Torregrosa JV; Oppenheimer F
Transplant Proc; 2012 Nov; 44(9):2582-4. PubMed ID: 23146461
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular risk profile in kidney transplant recipients treated with two immunosuppressive regimens: tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine.
Spagnoletti G; Citterio F; Favi E; Rossi E; Delreno F; De Santis I; Salerno MP; Gargiulo A; Castagneto M
Transplant Proc; 2009 May; 41(4):1175-7. PubMed ID: 19460509
[TBL] [Abstract][Full Text] [Related]
10. Conversion from cyclosporine to tacrolimus improves quality-of-life indices, renal graft function and cardiovascular risk profile.
Artz MA; Boots JM; Ligtenberg G; Roodnat JI; Christiaans MH; Vos PF; Moons P; Borm G; Hilbrands LB
Am J Transplant; 2004 Jun; 4(6):937-45. PubMed ID: 15147428
[TBL] [Abstract][Full Text] [Related]
11. Prospective randomized study of conversion from tacrolimus to cyclosporine A to improve glucose metabolism in patients with posttransplant diabetes mellitus after renal transplantation.
Wissing KM; Abramowicz D; Weekers L; Budde K; Rath T; Witzke O; Broeders N; Kianda M; Kuypers DRJ
Am J Transplant; 2018 Jul; 18(7):1726-1734. PubMed ID: 29337426
[TBL] [Abstract][Full Text] [Related]
12. Conversion from tacrolimus to cyclosporin is associated with a significant improvement of glucose metabolism in patients with new-onset diabetes mellitus after renal transplantation.
Bouchta NB; Ghisdal L; Abramowicz D; Broeders N; Surquin M; Hoang AD; Wissing KM
Transplant Proc; 2005 May; 37(4):1857-60. PubMed ID: 15919485
[TBL] [Abstract][Full Text] [Related]
13. Effects of cyclosporine-tacrolimus switching in posttransplantation hyperlipidemia on high-density lipoprotein 2/3, lipoprotein a1/b, and other lipid parameters.
Seymen P; Yildiz M; Türkmen MF; Titiz MI; Seymen HO
Transplant Proc; 2009 Dec; 41(10):4181-3. PubMed ID: 20005364
[TBL] [Abstract][Full Text] [Related]
14. Tacrolimus as secondary intervention vs. cyclosporine continuation in patients at risk for chronic renal allograft failure.
Waid T;
Clin Transplant; 2005 Oct; 19(5):573-80. PubMed ID: 16146546
[TBL] [Abstract][Full Text] [Related]
15. Conversion from tacrolimus to cyclosporine could improve control of posttransplant diabetes mellitus after renal transplantation.
Ramos-Cebrián M; Torregrosa JV; Gutiérrez-Dalmau A; Oppenheimer F; Campistol JM
Transplant Proc; 2007 Sep; 39(7):2251-3. PubMed ID: 17889154
[TBL] [Abstract][Full Text] [Related]
16. Glucose metabolism in the first 3 years after renal transplantation in patients receiving tacrolimus versus cyclosporine-based immunosuppression.
van Duijnhoven EM; Christiaans MHL; Boots JMM; Nieman FHM; Wolffenbuttel BHR; van Hooff JP
J Am Soc Nephrol; 2002 Jan; 13(1):213-220. PubMed ID: 11752040
[TBL] [Abstract][Full Text] [Related]
17. Improvement of cardiovascular risk factors and cosmetic side effects in kidney transplant recipients after conversion to tacrolimus.
Zadrazil J; Horak P; Zahalkova J; Strebl P; Horcicka V; Krejci K; Bachleda P; Dedochova J; Valkovsky I
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2009 Mar; 153(1):67-73. PubMed ID: 19365530
[TBL] [Abstract][Full Text] [Related]
18. Conversion from tacrolimus to cyclosporine in patients with new-onset diabetes after renal transplant: an open-label randomized prospective pilot study.
Rathi M; Rajkumar V; Rao N; Sharma A; Kumar S; Ramachandran R; Kumar V; Kohli HS; Gupta KL; Sakhuja V
Transplant Proc; 2015 May; 47(4):1158-61. PubMed ID: 26036543
[TBL] [Abstract][Full Text] [Related]
19. Glucose metabolism after pancreas transplantation: cyclosporine versus tacrolimus.
Dieterle CD; Schmauss S; Veitenhansl M; Gutt B; Illner WD; Land W; Landgraf R
Transplantation; 2004 May; 77(10):1561-5. PubMed ID: 15239622
[TBL] [Abstract][Full Text] [Related]
20. One-year observation of kidney allograft recipients converted from cyclosporine microemulsion to tacrolimus.
Chamienia A; Biedunkiewicz B; Król E; Debska-Slizień A; Rutkowski B
Transplant Proc; 2006; 38(1):81-5. PubMed ID: 16504670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
